Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.55 |
| ▸ | MME | P08473 | 5/20 | 0.53 |
| ▸ | LAP3 | P28838 | 3/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14163018 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL7361837 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL15649314 | 0.96 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4572627 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL6374251 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL15223612 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL29851595 | 0.85 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| SCHEMBL4833512 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Alanyl-Dl-Leucine SCHEMBL1171451 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT | |
| Alanyl-Dl-Leucine SCHEMBL1171453 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MEN1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARM INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3615019-B1 | MODULATOR OF SESTRIN-GATOR2 INTERACTION FOR USE IN THE TREATMENT OF TREATMENT-RESISTANT DEPRESSION | NAVITOR PHARM INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4556069-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-116370448-A | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| CN-110809467-B | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4112611-A2 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070518-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2009103941-A1 | CHEMICAL MODIFICATION OF PROTEINS | ISIS INNOVATION LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
| CN-1326870-C | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2007-07-18 | — | — | CN | disclosed |
| CN-1675236-A | Antibacterial amide macrocycles | BAYER HEALTHCARE AG (DE) | 2005-09-28 | — | — | CN | disclosed |
| EP-0415981-A4 | RETROVIRAL PROTEASE INHIBITORS | — | 1991-10-09 | — | — | EP | disclosed |
| EP-0415981-A1 | RETROVIRAL PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
| WO-1989010752-A1 | RETROVIRAL PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ALDH1A1 289/4885MEN1 511/4885LMNA 4266/4885 |
| US-20260034084-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | RICTOR, RPTOR, MTOR | ALDH1A1 3529/4885MEN1 2000/4885LMNA 3786/4885 |
| US-20240091184-A1 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF | GATD3, GABRR2, GABRR3 | ALDH1A1 3585/4885MEN1 2509/4885LMNA 4731/4885 |
| US-12378263-B2 | Modulators of sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | ALDH1A1 3585/4885MEN1 2509/4885LMNA 4731/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | ALDH1A1 3585/4885MEN1 2509/4885LMNA 4731/4885 |
| US-12427130-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | ALDH1A1 3585/4885MEN1 2509/4885LMNA 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.